WuXi AppTec Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Wuxi WuXi WuXi KangDe New Drug Development Co., Ltd. (stock code: 603259.SH/2359. HK) provides integrated, end-to-end new drug research and production services for the global biopharmaceutical industry, with operating bases in Asia, Europe, North America, and other regions. Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers research and development barriers, helps customers improve research and development efficiency, and brings more breakthrough treatment plans to patients. Its service scope covers chemical drug research and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and other fields. In 2022, WuXi KangDe was rated as ESG (Environmental, Social, and Governance) AA by MSCI. At present, the company's empowerment platform is carrying R&D and innovation projects from more than 6000 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients around the world, and realizing the vision of "making the world without difficult drugs and difficult diseases" as soon as possible. |
| Headquarter | Wuxi |
| Establish Date | 12/1/2000 |
| Listed Code | 603259.SH |
| Listed Date | 5/8/2018 |
| Chairman | Ge Li. |
| CEO | Ge Li. |
| Website | www.wuxiapptec.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
